-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
.
According to the Eggshell Research Institute, in 2021, the scale of China's clinical mass spectrometry market has exceeded 10 billion RMB
.
With the development of proteome, metabolome and other multi-omics technologies, the application field of mass spectrometry in clinical practice is constantly expanding, the technology is becoming more and more mature, and the market scale of clinical mass spectrometry is expanding
.
As a result, enthusiasm for clinical mass spectrometry has been growing
on the investment side.
According to incomplete statistics from the chemical instrument network, in the first half of 2022, the financing of the mass spectrometry industry was mainly clinical mass spectrometry, and the related financing amount exceeded 1 billion yuan
.
In the second half of the year, clinical mass spectrometry is also the focus of
mass spectrometry financing.
According to incomplete statistics, there were 10 financings in the mass spectrometry industry in the second half of the year, of which 8 involved clinical mass spectrometry, including mass spectrometry products and mass spectrometry detection services
.
Although the amount of financing is not as large as in the first half of the year, it is also an absolute protagonist
.
.
In the second half of the year, clinical mass spectrometry is also the focus of
mass spectrometry financing.
According to incomplete statistics, there were 10 financings in the mass spectrometry industry in the second half of the year, of which 8 involved clinical mass spectrometry, including mass spectrometry products and mass spectrometry detection services
.
Although the amount of financing is not as large as in the first half of the year, it is also an absolute protagonist
.
Among the enterprises that will complete financing in the second half of 2022, Gloria Spectrum, Zhongke New Life, Yunjian Medical, and Baiqu Biotech mainly provide clinical mass spectrometry detection technologies including proteome and metabolome detection, which are used in cancer detection and clinical research.
Meihua Medical, Anyipu and Puyuan Biologics have developed mass spectrometry products for clinical testing; While providing clinical diagnostic mass spectrometry reagents, Qingzi also plans to develop domestic mass spectrometry instruments
.
Meihua Medical, Anyipu and Puyuan Biologics have developed mass spectrometry products for clinical testing; While providing clinical diagnostic mass spectrometry reagents, Qingzi also plans to develop domestic mass spectrometry instruments
.
From the perspective of financing amount, investment institutions invest heavily in mass spectrometry enterprises, often hundreds of millions of yuan
.
At the same time, many companies have accepted multiple rounds of financing
.
For example, Gloria completed a series C financing of hundreds of millions of yuan in the first half of 2022, and a series C + financing
of tens of millions of yuan in December.
This shows that investors are very optimistic about the future prospects of clinical mass spectrometry
.
.
At the same time, many companies have accepted multiple rounds of financing
.
For example, Gloria completed a series C financing of hundreds of millions of yuan in the first half of 2022, and a series C + financing
of tens of millions of yuan in December.
This shows that investors are very optimistic about the future prospects of clinical mass spectrometry
.
In recent years, the support of the capital market for clinical mass spectrometry is increasing rapidly, with only one public financing event in 2015, a significant increase in 2016, and the financing amount exceeded 1 billion yuan in 2021, and in 2022, the financing situation in the first half of the year alone was comparable
to that of the whole year of 2021.
to that of the whole year of 2021.
The hot capital market has made enterprises have enough funds to start product and technology research and development and clinical transformation
.
It is understood that the commercialization of clinical mass spectrometry has been initially successful, and more and more hospitals have begun to configure mass spectrometry instruments
in clinical laboratories.
The revenue scale of the first-echelon enterprises of clinical mass spectrometry has moved from tens of millions to hundreds of millions, which has enriched the confidence of investment institutions in the development prospects of clinical mass spectrometry
.
.
It is understood that the commercialization of clinical mass spectrometry has been initially successful, and more and more hospitals have begun to configure mass spectrometry instruments
in clinical laboratories.
The revenue scale of the first-echelon enterprises of clinical mass spectrometry has moved from tens of millions to hundreds of millions, which has enriched the confidence of investment institutions in the development prospects of clinical mass spectrometry
.
Moreover, the scientific research achievements of clinical mass spectrometry in disease marker detection and nucleic acid detection continue to emerge, which provides core competitiveness for the application of mass spectrometry technology in clinical practice
.
Although it is still in the scientific research stage at this stage, once these achievements are completed and transformed into large-scale applications, they will bring a new wave
of development to the clinical mass spectrometry market.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body). .
Although it is still in the scientific research stage at this stage, once these achievements are completed and transformed into large-scale applications, they will bring a new wave
of development to the clinical mass spectrometry market.
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];
